Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1

Status

Completed 30Terminated 8Recruiting 6Unknown 4Withdrawn 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Carcinoma, Non-Small-Cell Lung 22Cholangiocarcinoma 21Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Neoplasms 6Hodgkin Disease 6Gallbladder Neoplasms 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

Cyclophosphamide 13pembrolizumab 8Brentuximab Vedotin 8fludarabine 7Nivolumab 7Whole-Body Irradiation 6Specimen Handling 6Mycophenolic Acid 6Gemcitabine 6Etoposide 6Doxorubicin 6Dacarbazine 6fludarabine phosphate 5Vinblastine 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Dexamethasone 5Stem Cell Transplantation 4Cytarabine 4Vinorelbine 3Tacrolimus 3Magnetic Resonance Spectroscopy 3Cyclosporine 3Carmustine 3Blood Specimen Collection 3thymoglobulin 2polatuzumab vedotin 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Hodgkin Disease × Gemcitabine × Clear all
NCT06377566 2026-04-23

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
71 enrolled
Lymphoid

Hodgkin Disease

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
257 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Canadian Cancer Trials Group

Phase 2 Recruiting
84 enrolled
Lymphoid

Hodgkin Disease

NCT05300282 2026-01-28

FIL_A-BEGEV

Fondazione Italiana Linfomi - ETS

Phase 1/2 Recruiting
122 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Recruiting
185 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡